Business Context and Reporting Period
Rani Therapeutics Holdings, Inc. (RANI) filed a Form 8-K on June 20, 2025, reporting a regulatory event concerning its listing status on The Nasdaq Global Market. The company is incorporated in Delaware and operates as an emerging growth company.
Key Financial Metrics
This filing does not provide specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity figures. The report focuses exclusively on the company's stock price performance relative to exchange listing requirements.
Material Changes
The material change reported is the failure of the Company's Class A common stock to maintain the minimum bid price requirement of $1.00 per share for 30 consecutive business days. Consequently, the Company received a notice of noncompliance from Nasdaq under Listing Rule 5450(a)(1).
Outlook, Risks, and Contingencies
- Compliance Period: The Company has a 180-day period ending December 17, 2025, to regain compliance.
- Remediation Requirement: To cure the deficiency, the stock must maintain a minimum bid price of at least $1.00 for 10 consecutive business days.
- Extension Option: If compliance is not met by the initial deadline, the Company may be eligible for an additional 180-day period if it transfers to The Nasdaq Capital Market, provided it meets other listing standards (excluding the bid price) and potentially effects a reverse stock split.
- Delisting Risk: Failure to regain compliance within the granted periods will result in the delisting of the Common Stock.
- Management Commentary: Management intends to monitor the stock price and consider available options to resolve the noncompliance but noted there is no assurance of regaining compliance or receiving further extensions.
Investor Verification Checklist
- Verify the current closing bid price of RANI stock to assess proximity to the $1.00 threshold.
- Monitor the Company's announcements regarding potential reverse stock splits or transfer to The Nasdaq Capital Market.
- Review the Company's cash position in other filings to determine if it has sufficient liquidity to execute a reverse stock split if necessary.
- Track the 10 consecutive business day window required to demonstrate compliance before the December 17, 2025 deadline.